Merck & Co., Inc. (MRK) Gross Margin: 75.91%
Is Merck & Co., Inc.’s gross margin high or low?
Merck & Co., Inc.'s gross margin of 75.91% is in line with its 5-year average of 71.89%, near the high end of its 5-year range (67.20%–76.32%).
The gross margin for Merck & Co., Inc. (MRK) is 75.91% as of Wednesday, June 10, 2026. It is above its 12-month average by 2.37% (74.15%).
MRK Gross Margin Chart
MRK Average Gross Margin Chart
MRK Current vs Average Gross Margin Chart
MRK Gross Margin Metrics
GROSS MARGIN
75.91%
GROSS MARGIN AVG TTM
74.15%
GROSS MARGIN AVG 3Y
73.03%
GROSS MARGIN AVG 5Y
71.89%
GROSS MARGIN AVG 10Y
69.40%
GROSS MARGIN AVG 15Y
67.21%
GROSS MARGIN AVG 20Y
68.75%
CURRENT VS TTM AVG
+2.37%
CURRENT VS 3Y AVG
+3.95%
CURRENT VS 5Y AVG
+5.60%
CURRENT VS 10Y AVG
+9.38%
CURRENT VS 15Y AVG
+12.95%
CURRENT VS 20Y AVG
+10.41%
MRK Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $293.02B | 75.91% | 74.15% | 73.03% | 71.89% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 18.80% | 20.43% | 22.48% | 23.36% |
| AbbVie Inc. (ABBV) | $399.54B | 70.68% | 70.11% | 68.16% | 68.00% |
| Amgen Inc. (AMGN) | $183.75B | 71.46% | 66.16% | 69.53% | 71.51% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 39.41% | 39.50% | 40.36% | 43.54% |
| Abbott Laboratories (ABT) | $154.66B | 56.38% | 53.17% | 51.86% | 51.92% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 79.35% | 78.55% | 78.10% | 78.28% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 66.29% | 66.73% | 66.82% | 67.04% |
| Pfizer Inc. (PFE) | $146.36B | 69.35% | 68.05% | 62.23% | 63.06% |
| Danaher Corporation (DHR) | $130.25B | 60.68% | 60.22% | 59.98% | 59.48% |
Gross Margin Analysis
Gross Margin
75.9%
(Revenue - COGS) / Revenue
Merck & Co., Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Gross Margin FAQ
- What is the gross margin for Merck & Co., Inc. (MRK)?
- The gross margin for MRK stock is 75.91%.
- Is Merck & Co., Inc.'s gross margin high or low?
- Merck & Co., Inc.'s gross margin of 75.91% is in line with its 5-year average of 71.89%, near the high end of its 5-year range (67.20%–76.32%).
- What is the TTM average gross margin for Merck & Co., Inc. (MRK)?
- The TTM average gross margin for MRK stock is 74.15%.
- What is the 3Y average gross margin for Merck & Co., Inc. (MRK)?
- The 3Y average gross margin for MRK stock is 73.03%.
- What is the 5Y average gross margin for Merck & Co., Inc. (MRK)?
- The 5Y average gross margin for MRK stock is 71.89%.
- What is the 10Y average gross margin for Merck & Co., Inc. (MRK)?
- The 10Y average gross margin for MRK stock is 69.40%.
- What is the 15Y average gross margin for Merck & Co., Inc. (MRK)?
- The 15Y average gross margin for MRK stock is 67.21%.
- What is the 20Y average gross margin for Merck & Co., Inc. (MRK)?
- The 20Y average gross margin for MRK stock is 68.75%.
Merck & Co., Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 71.98% |
| 2024-12-31 | 76.32% |
| 2023-12-31 | 73.17% |
| 2022-12-31 | 70.63% |
| 2021-12-31 | 72.02% |
| 2020-12-31 | 67.20% |
| 2019-12-31 | 69.29% |
| 2018-12-31 | 68.06% |
| 2017-12-31 | 67.82% |
| 2016-12-31 | 64.75% |
| 2015-12-31 | 62.19% |
| 2014-12-31 | 60.30% |
| 2013-12-31 | 61.50% |
| 2012-12-31 | 65.21% |
| 2011-12-31 | 64.89% |
| 2010-12-31 | 60.00% |
| 2009-12-31 | 67.12% |
| 2008-12-31 | 76.59% |
| 2007-12-31 | 74.62% |
| 2006-12-31 | 73.49% |
| 2005-12-31 | 76.61% |
| 2004-12-31 | 78.38% |
| 2003-12-31 | 80.27% |
| 2002-12-31 | 81.78% |
| 2001-12-31 | 82.90% |
| 2000-12-31 | 47.56% |
| 1999-12-31 | 49.90% |
| 1998-12-31 | 51.02% |
| 1997-12-31 | 53.66% |
| 1996-12-31 | 56.69% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis